Isoform P53 Protein, a Marker Unfavorable Prognostic in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukaemia P53 gene Intrinsic apoptosis CD-5 receptor, Non-Hodgkin lymphoma.



The paper highlights the stages of Chronic Lymphocytic Leukemia  B type, (CLL-B), which did not meet the standard treatment criteria for malignant hematological diseases due to P53 gene mutations, with progression to diffuse large lymphoma.

The mutated P53 gene is the most common genetic abnormality in cancer and has been studied in various mature B-cell malignancies, including chronic lymphocytic leukemia (CLL). The identification of the mutated P53 gene is very important because this mutation has an impact on the clinical course of patients in CLL with the p53 protein isoform.

The frequency of p53 protein expression in 85 patients diagnosed with CLL was analyzed by the ELISA (Enzyme Linked Immune-Absorbent Assay) technique, investigating the relationship of this protein with the stage of the disease and the impact on treatment response and survival. Cell extracts 10³×10³/L in 100 μl lysis buffer were applied to ELISA plates coated with PAb 240 antibodies, specific antibodies for isoform p53 protein. The average concentrations of p53 proteins in 17 of the 20 cases were found to be 16.76 μg / dl, with CV = 0.5% and the probability index p = 0.034. The study was done from sample blood patients included in screening analyses from a diagnosis of leukemia, as a clinical trial of phase I.

ELISA method has proven to be a useful prognostic tool for CLL for the application of personalized treatment in cases diagnosed with CLL resistance to the specific treatment applied by the first line with standard onco-immune therapy. 


Download data is not yet available.